Who is sponsoring NCT05650827?

NCT05650827 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT05650827?

Interventions in NCT05650827: Resistance training, Protein supplement.

What condition does NCT05650827 study?

NCT05650827 studies Gastro-esophageal Cancer.

Is NCT05650827 still recruiting?

NCT05650827 is currently active, enrolled. Last updated 14 May 2025.

Last reviewed 2025-05-14 · How we verify

NCT05650827

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility and Effect of Resistance Training and Protein Supplementation in Patients With Advanced Gastroesophageal Cancer

Active, enrolled NA Last updated 14 May 2025

What this trial tests

NA trial testing Resistance training in Gastro-esophageal Cancer in 54 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

24 February 2023

Primary endpoint
31 December 2024

31 December 2027

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	54
Start date	24 February 2023
Primary completion	31 December 2024
Estimated completion	31 December 2027
Sites	1 location across Denmark

Drugs / interventions tested

Resistance training
Protein supplement — full drug profile →

Conditions studied

Gastro-esophageal Cancer — all drugs for Gastro-esophageal Cancer →

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Gastro-esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with advanced gastroesophageal cancer are in great risk of losing skeletal muscle mass and developing cancer cachexia. Low skeletal muscle mass has a negative impact on quality of life, impairs physical function, increases toxicity from anti-neoplastic treatment, as well as increases risk of death. Resistance training and protein supplements have the potential to stimulate muscle anabolism and counteract loss of skeletal muscle mass. Therefore, the investigators have designed a randomized controlled feasibility trial to evaluate the feasibility, safety and the therapeutic effect of resistance training and protein supplements in patients with advanced gastroesophageal cancer undergoing first line chemotherapy. A total of 54 patients with advanced gastroesophageal cancer will be recruited from the Department of Oncology, Copenhagen University Hospital, Rigshospitalet and randomly allocated 2:1 to standard care plus resistance training 3 times pr. week and a daily supplement of protein or to standard care alone.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis.
Li Y, Cheng Y, Cai Y, Duan Z, et al · · 2025 · cited 4× · PMID 40299379 · DOI 10.3390/biomedicines13040781
Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.
Okamura M, Shirado K, Shirai N, Yagi T, et al · · 2026 · PMID 41884877 · DOI 10.2490/prm.20260012

Verify or expand the search:

Other trials of Resistance training

Trials testing the same drug.

NCT07166198 — Mitigating Neural Hypoexcitability and Weakness During Disuse in Women · NA · not yet recruiting
NCT07411625 — Preoperative Rehabilitation for Patient With an ACL Injury · NA · recruiting
NCT07484776 — Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer · NA · active not recruiting
NCT07341698 — Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplant · NA · recruiting
NCT07058818 — Tailored Resistance Training After Adverse Pregnancy Outcomes · NA · completed

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05650827 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 14 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05650827.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing